Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
I'm PortAI, I can summarize articles.
Mabwell announced the first patient dosing in the Phase I/II clinical trial of its novel CDH17-targeting ADC, 7MW4911, for advanced solid tumors. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 7MW4911. Preclinical studies showed potent antitumor activity, especially in multidrug-resistant models. 7MW4911 had previously received FDA IND clearance for advanced colorectal and gastrointestinal tumors.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments